Shabir A Madhi1, Nigel A Cunliffe2, Duncan Steele3, Desirée Witte4, Mari Kirsten5, Cheryl Louw6, Bagrey Ngwira7, John C Victor8, Paul H Gillard9, Brigitte B Cheuvart9, Htay H Han9, Kathleen M Neuzil8. 1. Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa. 2. Division of Medical Microbiology, University of Liverpool, Liverpool, United Kingdom. 3. Initiative for Vaccine Research, World Health Organization, Geneva. 4. Division of Medical Microbiology, University of Liverpool, Liverpool, United Kingdom; College of Medicine, University of Malawi, Blantyre, Malawi. 5. Department of Paediatric Surgery, University of Pretoria, Pretoria, South Africa. 6. Madibeng Center for Research, Brits, South Africa; Medical Research Council Diarrhoeal Pathogens Research Unit, University of Limpopo, Limpopo, South Africa. 7. College of Medicine, University of Malawi, Blantyre, Malawi. 8. Rotavirus Vaccine Program, PATH, Seattle, Washington, U.S.A. 9. GlaxoSmithKline Biologicals, Rixensart, Belgium.
Abstract
BACKGROUND: Rotavirus is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. METHODS: We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to evaluate the efficacy of a live, oral rotavirus vaccine in preventing severe rotavirus gastroenteritis. Healthy infants were randomly assigned in a 1:1:1 ratio to receive two doses of vaccine (in addition to one dose of placebo) or three doses of vaccine - the pooled vaccine group - or three doses of placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis caused by wild-type rotavirus during the first year of life were assessed through active follow-up surveillance and were graded with the use of the Vesikari scale. RESULTS: A total of 4939 infants were enrolled and randomly assigned to one of the three groups; 1647 infants received two doses of the vaccine, 1651 infants received three doses of the vaccine, and 1641 received placebo. Of the 4417 infants included in the per-protocol efficacy analysis, severe rotavirus gastroenteritis occurred in 4.9% of the infants in the placebo group and in 1.9% of those in the pooled vaccine group (vaccine efficacy, 61.2%; 95% confidence interval, 44.0 to 73.2). Vaccine efficacy was lower in Malawi than in South Africa (49.4% vs. 76.9%); however, the number of episodes of severe rotavirus gastroenteritis that were prevented was greater in Malawi than in South Africa (6.7 vs. 4.2 cases prevented per 100 infants vaccinated per year). Efficacy against all-cause severe gastroenteritis was 30.2%. At least one serious adverse event was reported in 9.7% of the infants in the pooled vaccine group and in 11.5% of the infants in the placebo group. CONCLUSIONS: Human rotavirus vaccine significantly reduced the incidence of severe rotavirus gastroenteritis among African infants during the first year of life. (ClinicalTrials.gov number, NCT00241644.).
BACKGROUND: Rotavirus is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. METHODS: We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to evaluate the efficacy of a live, oral rotavirus vaccine in preventing severe rotavirus gastroenteritis. Healthy infants were randomly assigned in a 1:1:1 ratio to receive two doses of vaccine (in addition to one dose of placebo) or three doses of vaccine - the pooled vaccine group - or three doses of placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis caused by wild-type rotavirus during the first year of life were assessed through active follow-up surveillance and were graded with the use of the Vesikari scale. RESULTS: A total of 4939 infants were enrolled and randomly assigned to one of the three groups; 1647 infants received two doses of the vaccine, 1651 infants received three doses of the vaccine, and 1641 received placebo. Of the 4417 infants included in the per-protocol efficacy analysis, severe rotavirus gastroenteritis occurred in 4.9% of the infants in the placebo group and in 1.9% of those in the pooled vaccine group (vaccine efficacy, 61.2%; 95% confidence interval, 44.0 to 73.2). Vaccine efficacy was lower in Malawi than in South Africa (49.4% vs. 76.9%); however, the number of episodes of severe rotavirus gastroenteritis that were prevented was greater in Malawi than in South Africa (6.7 vs. 4.2 cases prevented per 100 infants vaccinated per year). Efficacy against all-cause severe gastroenteritis was 30.2%. At least one serious adverse event was reported in 9.7% of the infants in the pooled vaccine group and in 11.5% of the infants in the placebo group. CONCLUSIONS: Human rotavirus vaccine significantly reduced the incidence of severe rotavirus gastroenteritis among African infants during the first year of life. (ClinicalTrials.gov number, NCT00241644.).
Authors: K Zaman; D A Sack; M Yunus; S E Arifeen; G Podder; T Azim; S Luby; R F Breiman; K Neuzil; S K Datta; A Delem; P V Suryakiran; H L Bock Journal: Vaccine Date: 2009-01-20 Impact factor: 3.641
Authors: M C Georges-Courbot; J Monges; M R Siopathis; J B Roungou; G Gresenguet; L Bellec; J C Bouquety; C Lanckriet; M Cadoz; L Hessel Journal: Res Virol Date: 1991 Sep-Oct
Authors: T V Murphy; P M Gargiullo; M S Massoudi; D B Nelson; A O Jumaan; C A Okoro; L R Zanardi; S Setia; E Fair; C W LeBaron; M Wharton; J R Livengood; J R Livingood Journal: N Engl J Med Date: 2001-02-22 Impact factor: 91.245
Authors: C H Simanjuntak; F P Paleologo; N H Punjabi; R Darmowigoto; H Totosudirjo; P Haryanto; E Suprijanto; N D Witham; S L Hoffman Journal: Lancet Date: 1991-10-26 Impact factor: 79.321
Authors: Nigel A Cunliffe; Bagrey M Ngwira; Winifred Dove; Osamu Nakagomi; Toyoko Nakagomi; Arantza Perez; C Anthony Hart; Peter N Kazembe; Charles C V Mwansambo Journal: Emerg Infect Dis Date: 2009-01 Impact factor: 6.883
Authors: Leslie P Jamka; Kenneth W Simiyu; Adwoa D Bentsi-Enchill; Aziza J Mwisongo; Helen Matzger; Anthony A Marfin; Andrew J Pollard; Kathleen M Neuzil Journal: Clin Infect Dis Date: 2019-03-07 Impact factor: 9.079